ImmunoCellular Therapeutics, Ltd’ Data From Phase I Trial of ICT-107 Accepted for Publication in Prestigious Medical Journal, Cancer Immunology, Immunotherapy
Published: Aug 08, 2012
LOS ANGELES--(BUSINESS WIRE)--ImmunoCellular Therapeutics (NYSE MKT: IMUC) announced today that clinical data from its Phase I trial of ICT-107 was accepted for publication, and is currently in the online edition of the prestigious medical journal Cancer Immunology, Immunotherapy (http://www.springerlink.com/content/n0018574g9m4v587/fulltext.pdf). In the publication, the data showed that the expression of four ICT-107 targeted antigens in the pre-vaccine tumors correlated with longer overall survival (OS) and progression free survival (PFS) in newly diagnosed glioblastoma multiforme (GBM) patients. Median PFS in newly diagnosed GBM patients was 16.9 months and median OS was 38.4 months.